VALN - Pfizer Valneva's Tick-Borne Infection Shot: Companies Say 'Positive' Result For Lyme Disease Vaccine Candidate Booster | Benzinga
Valneva SE (NASDAQ: VALN) and Pfizer Inc (NYSE: PFE) released pediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate, VLA15, when given as a booster.
Lyme disease is a bacterial infection that can be spread to humans by infected ticks.
The study showed a robust anamnestic antibody response for all serotypes in pediatric (5 to 11 years of age) and adolescent participants (12 to 17 years of age), as well as in adults, one month after administration of a booster dose (month 19).
Depending on the primary ...